Search for new antitumor compounds among n-glycoside indolo[2,3-a]carbazole derivatives
- Authors: Kiseleva M.P.1, Smirnova Z.S1, Borisova L.M1, Kubasova I.Y.1, Ektova L.V1, Miniker T.D1, Plikhtiak I.L1, Medvedeva L.A1, Eremina V.A1, Tikhonova N.I1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 20, No 1 (2015)
- Pages: 33-37
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40133
- DOI: https://doi.org/10.17816/onco40133
- ID: 40133
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Marina P. Kiseleva
N.N. Blokhin Russian Cancer Research Center
Email: marina-kiselyova@mail.ru
MD 115478, Moscow, Russian Federation
Z. S Smirnova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
L. M Borisova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
I. Yu Kubasova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
L. V Ektova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
T. D Miniker
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
I. L Plikhtiak
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
L. A Medvedeva
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
V. A Eremina
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
N. I Tikhonova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
References
- Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells (invited review). Cur. Drug Targets. 2001; 2: 57-77.
- Bridges J.A. Chemical inhibitors of protein kinases. Chem. Rev. 2001; 101: 2541-71.
- Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents. 2003; 3 (4): 271-90.
- Pindur U., Kim Y-S., Meharbani F. Advances in indolo 2,3-a. carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Cur. Med. Chem. 1999; 6: 29-68.
- Kleinschrot J., Hartenstein J., Rudolf C., Schachtele C. Novel indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties. Bio-org. Med. Chem. Lett. 1995; 5: 55-60.
- Meng L.-H., Liao Z.-Y., Pommier Y. Non-camptothecin DNK topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem. 2003; 3 (3): 305-20.
- Bush J.A., Long B.H., Catino J.J., Bradner W.T. Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiot. 1987; 40: 668-78.
- Yoshinari T., Yamada A., Uemura D., Nomura K., Arakawa H., Kojiri K. et al. Induction of topoisomerase I mediated DNA cleavage by a new indolocarbazole ED-1101. Cancer Res. 1993; 53: 490-4.
- Schwandt A., Mekhail T., Halmos B. et al. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed “sensitive» small cell lung cancer. J. Thorac. Oncol. 2012; 7(4): 751-4.
- Prudhomme M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Curr. Med. Chem. Anti-cancer Agents. 2004; 4: 509-21.
- Колс Ян. Применение Мидостаурина для лечения желудочно-кишечных стромальных опухолей. Патент РФ № 2410098, 2011.
- Мельник С.Я. Синтез и изучение гликозидов, производных бисиндола и родственных индоло[2,3-а]карбазолов. В кн.: Давыдов М.И., Барышников А.Ю., ред. В кн.: Экспериментальная онкология на рубеже веков. М.; 2003: 281-93.
- Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К.; 2012: 642-56.
- Софьина З.П., Сыркин А.Б. (СССР), Голдин А., Кляйн А. (США), ред. Экспериментальная оценка противоопухолевых препаратов в СССР и США. М.: Медицина; 1979.